Fact CheckerSign in

NCT06459791Recruiting

Efficacy of Personalized Tumorogram-based Therapy in Cancer Established From Patient-derived Organoid (AVATAR)

Efficacy of Personalized Tumorogram-based Therapy in Cancer Established From Patient-derived Biological Avatar: Proof-of-concept Study

Source: ClinicalTrials.gov · Last updated 29 Jan 2026

Brief summary (registry, in English)

A biopsy of a tumor lesion (breast or other localisation) will be performed for processing to establish avatars (patient-derived organoids -PDO). A personalized tumorogram for each patient will be provided, based on the results of the drug screening (= tumor predicted as sensitive, intermediate, resistant or non-evaluable for each drug tested). Patients with an informative tumorogram will receive one of the recommended treatments (line N+1) in the event of tumor progression, administered according to standard procedures and validated at medical meetings specific to each center, and their fate will be monitored.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
110 (estimated)
First submitted
27 May 2024
Start date
6 Dec 2024
Primary completion date
15 Dec 2027
Lead sponsor
Institut Curie
NCT number
NCT06459791

What you commit to

  • Study type: Interventional
  • Planned participants: 110
  • From 6 Dec 2024 to the primary completion date, 15 Dec 2027
  • 3 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • More than 3 lines of chemotherapy in the advanced setting (excluding hormone therapy/CDK4/6 inhibitor)

Other

  • Progressive brain metastases
  • Leptomeningeal metastasis

Who the study is looking for

  • Patient over 18 years of age
  • Advanced breast cancer
  • Triple-negative phenotype (HR-/HER2-) or HR+/HER2- after hormone resistance (progression after treatment with hormone therapy + CDK4/6 inhibitor)
  • Tumor measurable according to RECISTv1.1 criteria, accessible to biopsy
  • Performans Status 0-1

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (3)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Hôpital Saint-Louis - AP-HP Senopole
Coordinator of this site? Confirm its status
ParisFranceNot yet recruiting
Institut Curie
Coordinator of this site? Confirm its status
ParisFranceRecruiting
Institut Curie
Coordinator of this site? Confirm its status
Saint-CloudFranceRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.